TY  - JOUR
AU  - Sequist, Lecia V
AU  - Gray, Jhanelle Elaine
AU  - Harb, Wael A
AU  - Lopez-Chavez, Ariel
AU  - Doebele, Robert C
AU  - Modiano, Manuel R
AU  - Jackman, David Michael
AU  - Baggstrom, Maria Quintos
AU  - Atmaca, Akin
AU  - Felip, Enriqueta
AU  - Provencio, Mariano
AU  - Cobo, Manuel
AU  - Adiwijaya, Bambang
AU  - Kuesters, Geoffrey
AU  - Kamoun, Walid S
AU  - Andreas, Karen
AU  - Pipas, J Marc
AU  - Santillana, Sergio
AU  - Cho, Byoung Chul
AU  - Park, Keunchil
AU  - Shepherd, Frances A
PY  - 2019
DO  - 10.1634/theoncologist.2018-0695
UR  - http://hdl.handle.net/10668/13817
T2  - The oncologist
AB  - Seribantumab (MM-121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block heregulin (HRG/NRG)-mediated ErbB3 signaling and induce receptor downregulation. This open-label, randomized...
LA  - en
KW  - Antibody
KW  - Biomarkers
KW  - HER3/ErbB3
KW  - Heregulin
KW  - Seribantumab
KW  - Targeted therapy
KW  - Translational
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Carcinoma, Non-Small-Cell Lung
KW  - ErbB Receptors
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Lung
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neuregulin-1
KW  - Patient Selection
KW  - Progression-Free Survival
KW  - Receptor, ErbB-3
KW  - Retrospective Studies
TI  - Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
TY  - research article
VL  - 24
ER  -